24-hour Lung Function in Subjects with Moderate to Very Severe COPD after Treatment with PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Trial Identifier: PT003011-00
Sponsor: Pearl Therapeutics, Inc.
NCTID:: NCT02347072
Start Date: February 2015
Primary Completion Date: August 2015
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.